PMID- 20032435
OWN - NLM
STAT- MEDLINE
DCOM- 20100126
LR  - 20111117
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 29
IP  - 11
DP  - 2009 Nov
TI  - Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
PG  - 4779-84
AB  - BACKGROUND: The object of this study was to investigate the safety and clinical 
      response of immunotherapy targeting the WT1 (Wilms' tumor 1) gene product in 
      patients with gynecological cancer. PATIENTS AND METHODS: Twelve patients with 
      WT1/human leukocyte antigen (HLA)-A*2402-positive gynecological cancer were 
      included in a Phase II clinical trial of WT1 vaccine therapy. In all the 
      patients, the tumors were resistant to standard therapy. The patients received 
      intradermal injections of a HLA-A*2402-restricted, modified 9-mer WT1 peptide 
      every week for 12 weeks. Tumor size, which was measured by computed tomography 
      (CT), was determined every 4 weeks. The responses were analyzed according to 
      Response Evaluation Criteria in Solid Tumors (RECIST). RESULTS: The protocol was 
      well tolerated; only local erythema occurred at the WT1 vaccine injection site. 
      The clinical responses were as follows: stable disease (SD) in 3 patients and 
      progressive disease (PD) in 9 patients. No patients had a complete (CR) or 
      partial response (PR). The disease control rate was 25.0%. CONCLUSION: Although a 
      small, uncontrolled, nonrandomized trial, this study showed that WT1 vaccine 
      therapy for patients with gynecological cancer was safe and produced a clinical 
      response.
FAU - Ohno, Satoshi
AU  - Ohno S
AD  - International Research and Educational Institute for Integrated Medical Sciences, 
      Tokyo Women's Medical University, Tokyo, 162-8666, Japan. 
      satoshi.ohno55@gmail.com
FAU - Kyo, Satoru
AU  - Kyo S
FAU - Myojo, Subaru
AU  - Myojo S
FAU - Dohi, Satoshi
AU  - Dohi S
FAU - Ishizaki, Junko
AU  - Ishizaki J
FAU - Miyamoto, Ken-Ichi
AU  - Miyamoto K
FAU - Morita, Satoshi
AU  - Morita S
FAU - Sakamoto, Jun-Ichi
AU  - Sakamoto J
FAU - Enomoto, Takayuki
AU  - Enomoto T
FAU - Kimura, Tadashi
AU  - Kimura T
FAU - Oka, Yoshihiro
AU  - Oka Y
FAU - Tsuboi, Akihiro
AU  - Tsuboi A
FAU - Sugiyama, Haruo
AU  - Sugiyama H
FAU - Inoue, Masaki
AU  - Inoue M
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A*24:02 antigen)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Peptide Fragments)
RN  - 0 (WT1 Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cancer Vaccines/*therapeutic use
MH  - Female
MH  - Genital Neoplasms, Female/immunology/*therapy
MH  - HLA-A Antigens/biosynthesis/immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Injections, Intradermal
MH  - Middle Aged
MH  - Peptide Fragments/administration & dosage/immunology
MH  - WT1 Proteins/*immunology
EDAT- 2009/12/25 06:00
MHDA- 2010/01/27 06:00
CRDT- 2009/12/25 06:00
PHST- 2009/12/25 06:00 [entrez]
PHST- 2009/12/25 06:00 [pubmed]
PHST- 2010/01/27 06:00 [medline]
AID - 29/11/4779 [pii]
PST - ppublish
SO  - Anticancer Res. 2009 Nov;29(11):4779-84.